Bavarian Nordic A/S(CPH:BAVA), a fully integrated biotechnology company, reported on Tuesday additional positive data from its 421 patient, phase 2 study investigating the safety and immune effects of its universal RSV vaccine, MVA-BN RSV, in an older adult population.

Reportedly, in a planned follow-up analysis, nasal swabs demonstrated, on average, an approximately 1.5-fold increase in IgA antibodies over baseline levels, with peak increases seen in the weeks immediately following vaccination.

Also, the boosting effect was more pronounced in individuals with a lower baseline mucosal IgA at the time of vaccination. This observation suggests that the vaccine has the desired effect of boosting memory responses against RSV in patients with a poor underlying immunity.

According to the company. previous published studies have shown that in RSV human challenge studies, the presence of IgA antibodies in the mucosa is highly correlated with immune protection in subjects who do not develop symptoms of RSV. In those studies, the level of IgA expression seen was similar to the levels of expression detected post-vaccination with MVA-BN RSV.

Bavarian Nordic is focused on the development of innovative and safe therapies against cancer and infectious diseases. Using its live virus vaccine platform technology, MVA-BN®, it has created a diverse portfolio of proprietary and partnered product candidates intended to improve the health and quality of life for children and adults.